Disposition of 316 shares by Jonathan White of Haemonetics subject to Rule 16b-3
HAE Stock | USD 66.16 0.76 1.14% |
About 54% of Haemonetics' investor base is interested to short. The analysis of overall sentiment of trading Haemonetics stock suggests that many investors are impartial at this time. The current market sentiment, together with Haemonetics' historical and current headlines, can help investors time the market. In addition, many technical investors use Haemonetics stock news signals to limit their universe of possible portfolio assets.
Haemonetics | Build AI portfolio with Haemonetics Stock |
Filed transaction by Haemonetics Corp officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3
Read at macroaxis.com
Cash Flow Correlation
Haemonetics' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Haemonetics' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
Haemonetics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Haemonetics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Haemonetics Historical Investor Sentiment
Investor biases related to Haemonetics' public news can be used to forecast risks associated with an investment in Haemonetics. The trend in average sentiment can be used to explain how an investor holding Haemonetics can time the market purely based on public headlines and social activities around Haemonetics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Haemonetics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Haemonetics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Haemonetics news discussions. The higher the estimate score, the more favorable the investor's outlook on Haemonetics.
Haemonetics Maximum Pain Price Across July 18th 2025 Option Contracts
Haemonetics' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Haemonetics close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Haemonetics' options.
Haemonetics Fundamental Analysis
We analyze Haemonetics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Haemonetics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Haemonetics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Liabilities
Current Liabilities Comparative Analysis
Haemonetics is currently under evaluation in current liabilities category among its peers. Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Haemonetics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Haemonetics stock to make a market-neutral strategy. Peer analysis of Haemonetics could also be used in its relative valuation, which is a method of valuing Haemonetics by comparing valuation metrics with similar companies.
Peers
Haemonetics Related Equities
NVST | Envista Holdings | 1.38 | ||||
ATR | AptarGroup | 0.13 | ||||
ICUI | ICU Medical | 0.02 | ||||
COO | Cooper Companies, | 0.09 | ||||
RMD | ResMed | 0.12 | ||||
WST | West Pharmaceutical | 0.22 | ||||
HOLX | Hologic | 0.62 | ||||
TFX | Teleflex Incorporated | 0.84 | ||||
ATRC | AtriCure | 1.35 | ||||
MMSI | Merit Medical | 1.43 | ||||
ALC | Alcon AG | 1.60 | ||||
ANGO | AngioDynamics | 1.67 | ||||
AKYA | Akoya Biosciences | 3.08 |
Complementary Tools for Haemonetics Stock analysis
When running Haemonetics' price analysis, check to measure Haemonetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Haemonetics is operating at the current time. Most of Haemonetics' value examination focuses on studying past and present price action to predict the probability of Haemonetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Haemonetics' price. Additionally, you may evaluate how the addition of Haemonetics to your portfolios can decrease your overall portfolio volatility.
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |